CHICAGO, IL, USA I May 20, 2016 I ResQ Pharma, Inc., a biopharmaceutical company focused on ensuring reliable, global use of LipidRescue™ Therapy (LRT), a treatment for various lipophilic drug overdoses & poisonings, today announced the Company has submitted an Investigational New Drug (IND) application for LRT as a last resort in treating local anesthetic systematic toxicity (LAST) to U.S. Food & Drug Administration (FDA).
About LipidRescue™ Therapy (LRT)
LRT is ResQ Pharma’s lead product candidate which refers to the administration of a lipid emulsion with the intent of reducing the life-threatening clinical manifestations of toxicity from excessive doses of certain lipophilic drugs. It is already the opinion of the American Heart Association and American College of Medical Toxicology that where there is serious hemodynamic instability from local anesthetic drugs with high lipid solubility, LRT is a reasonable consideration for therapy, even if patient is not in cardiac arrest.
About ResQ Pharma
ResQ Pharma, Inc., is a biopharmaceutical company created to ensure reliable, global use of LRT, a treatment for various lipophilic drug overdoses & poisonings. For more information on ResQ Pharma, please visit www.LipidRescue.com. We are a member of iBIO’s PROPEL, EnterpriseWorks Chicago, Chicago Founders Circle, The BUNKER and MATTER! We are also a Qualified New Business Venture for the Illinois Investment Tax Credit Program.
SOURCE: ResQ Pharma
Post Views: 107
CHICAGO, IL, USA I May 20, 2016 I ResQ Pharma, Inc., a biopharmaceutical company focused on ensuring reliable, global use of LipidRescue™ Therapy (LRT), a treatment for various lipophilic drug overdoses & poisonings, today announced the Company has submitted an Investigational New Drug (IND) application for LRT as a last resort in treating local anesthetic systematic toxicity (LAST) to U.S. Food & Drug Administration (FDA).
About LipidRescue™ Therapy (LRT)
LRT is ResQ Pharma’s lead product candidate which refers to the administration of a lipid emulsion with the intent of reducing the life-threatening clinical manifestations of toxicity from excessive doses of certain lipophilic drugs. It is already the opinion of the American Heart Association and American College of Medical Toxicology that where there is serious hemodynamic instability from local anesthetic drugs with high lipid solubility, LRT is a reasonable consideration for therapy, even if patient is not in cardiac arrest.
About ResQ Pharma
ResQ Pharma, Inc., is a biopharmaceutical company created to ensure reliable, global use of LRT, a treatment for various lipophilic drug overdoses & poisonings. For more information on ResQ Pharma, please visit www.LipidRescue.com. We are a member of iBIO’s PROPEL, EnterpriseWorks Chicago, Chicago Founders Circle, The BUNKER and MATTER! We are also a Qualified New Business Venture for the Illinois Investment Tax Credit Program.
SOURCE: ResQ Pharma
Post Views: 107
